Codexis, Inc. (CDXS)
| Market Cap | 91.23M |
| Revenue (ttm) | 52.93M |
| Net Income (ttm) | -63.95M |
| Shares Out | 90.32M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,238,027 |
| Open | 1.050 |
| Previous Close | 1.070 |
| Day's Range | 1.000 - 1.070 |
| 52-Week Range | 1.000 - 4.150 |
| Beta | 2.47 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 11, 2026 |
About CDXS
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorp... [Read more]
Financial Performance
In 2024, Codexis's revenue was $59.35 million, a decrease of -15.39% compared to the previous year's $70.14 million. Losses were -$65.28 million, -14.38% less than in 2023.
Financial StatementsNews
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today ...
Codexis Achieves ISO 9001:2015 Certification
REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today th...
Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics
REDWOOD CITY, Calif., Jan. 7, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LG...
Codexis Announces Signing of Lease for GMP Manufacturing Facility
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis, Inc. (CDXS) Q3 2025 Earnings Call Transcript
Codexis, Inc. ( CDXS) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Georgia Erbez - CFO & Chief Business Officer Stephen Dilly Alison Moore - President, CEO & Director Britt...
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
REDWOOD CITY, Calif. , Oct. 29, 2025 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and Nitto Denko Avec...
Codexis to Report Third Quarter 2025 Financial Results on November 6
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis to Participate in Cantor Global Healthcare Conference
REDWOOD CITY, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis, Inc. (CDXS) Q2 2025 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Georgia L. Erbez - Chief Financial Officer Kevin Norrett - Chief Operating Officer Stephen...
Codexis Reports Second Quarter 2025 Financial Results
Announces revenue of $15.3M vs $14.1M analyst consensus estimate Six presentations featured ECO Synthesis® platform at 2025 TIDES USA annual meeting, including three from leading CDMO collaborators $2...
Codexis to Report Second Quarter 2025 Financial Results on August 13
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, to...
Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA
Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Codexis to Participate in Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced th...
Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive O...
Codexis Reports First Quarter 2025 Financial Results
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming ...
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes
Codexis to Report First Quarter 2025 Financial Results on May 14
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
Codexis Announces Byron Dorgan to Retire from Board of Directors
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Execut...
Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...
Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...
Codexis Appoints Christos Richards to Board of Directors
REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...
Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference
REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...
Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics
—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared t...